drugset / Trial / NCT01423539
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized, open-label, multicenter study will evaluate the efficacy and safety of navitoclax in addition to bendamustine and rituximab in patients with relapsed diffuse large B-cell lymphoma. Patients will be randomized to receive navitoclax in addition to bendamustine and rituximab or bendamustine and rituximab alone for 6 cycles.
Timeline
- Start
- 2011-10
- Primary completion
- 2014-02
- Completion
- 2014-02
Outcome
Outcome not reported
Stopped: “The NAVIGATE study has been terminated due to non-safety related reasons.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navitoclax | Small molecule | — | Oral |
| Background | Bendamustine | Small molecule | — | Intravenous |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |